$DYAI
Dyadic International Inc

2021 Q2 Form 10-Q Financial Statement

#000143774921012046 Filed on May 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2021 Q1 2020 Q1
Revenue $937.1K $460.5M $315.4K
YoY Change 78.74% 145924.38% -21.65%
Cost Of Revenue $829.5K $390.8M $278.2K
YoY Change 32.88% 140369.91% -15.16%
Gross Profit $107.6K $69.76M $37.19K
YoY Change -207.62% 187471.93% -50.16%
Gross Profit Margin 11.48% 15.15% 11.79%
Selling, General & Admin $1.748M $1.550M $1.650M
YoY Change 18.08% -6.06% 15.38%
% of Gross Profit 1624.35% 2.22% 4436.68%
Research & Development $2.209M $1.808B $755.5K
YoY Change 97.93% 239239.58% 9.11%
% of Gross Profit 2053.43% 2591.96% 2031.33%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.209M $1.808B $755.5K
YoY Change 97.93% 239239.58% 9.11%
Operating Profit -$3.867M -$3.321B -$2.383M
YoY Change 38.21% 139274.12% -2.41%
Interest Expense $20.90K $25.67M $168.4K
YoY Change -85.74% 15145.01% -36.93%
% of Operating Profit
Other Income/Expense, Net $20.90K $25.67M
YoY Change
Pretax Income -$3.846M -$3.290M -$2.210M
YoY Change 45.14% 48.87% 1.84%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.846M -$3.295M -$2.214M
YoY Change 45.06% 48.81% 1.79%
Net Earnings / Revenue -410.44% -0.72% -702.07%
Basic Earnings Per Share -$0.14 -$0.12
Diluted Earnings Per Share -$139.1K -$119.5K -$80.51K
COMMON SHARES
Basic Shares Outstanding 27.55M 27.55M 27.36M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q2 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.60M $27.23M $31.28M
YoY Change -19.57% -12.95% -21.31%
Cash & Equivalents $14.02M $13.06M $4.697M
Short-Term Investments $11.58M $14.18M $26.59M
Other Short-Term Assets $100.9K $220.0K $290.0K
YoY Change -83.19% -24.14% 0.0%
Inventory
Prepaid Expenses
Receivables $291.4K $385.0K $518.6K
Other Receivables $163.3K $160.0K $730.0K
Total Short-Term Assets $26.16M $27.99M $32.82M
YoY Change -22.44% -14.71% -20.55%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $284.7K $280.0K $2.520M
YoY Change -88.89%
Other Assets $6.172K $6.151K $50.49K
YoY Change 0.92% -87.82% -0.91%
Total Long-Term Assets $290.9K $290.9K $2.569M
YoY Change 4656.07% -88.68% 365.7%
TOTAL ASSETS
Total Short-Term Assets $26.16M $27.99M $32.82M
Total Long-Term Assets $290.9K $290.9K $2.569M
Total Assets $26.45M $28.28M $35.39M
YoY Change -21.6% -20.08% -15.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.435M $1.474M $653.4K
YoY Change 112.85% 125.57% -31.08%
Accrued Expenses $594.8K $277.7K $240.0K
YoY Change 57.3% 15.69% -20.78%
Deferred Revenue $258.7K $842.2K $242.4K
YoY Change 525.36% 247.4% 953.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.288M $2.594M $1.136M
YoY Change 100.71% 128.36% -10.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.288M $2.594M $1.136M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.288M $2.590M $1.140M
YoY Change 100.52% 127.19% -10.24%
SHAREHOLDERS EQUITY
Retained Earnings -$57.82M -$53.97M -$43.57M
YoY Change 25.1% 23.89% 23.7%
Common Stock $40.33K $39.81K $39.71K
YoY Change 1.5% 0.24% 1.91%
Preferred Stock
YoY Change
Treasury Stock (at cost) $18.90M $18.90M $18.90M
YoY Change 0.0% 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $23.16M $25.69M $34.25M
YoY Change
Total Liabilities & Shareholders Equity $26.45M $28.28M $35.39M
YoY Change -21.6% -20.08% -15.46%

Cashflow Statement

Concept 2021 Q2 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$3.846M -$3.295M -$2.214M
YoY Change 45.06% 48.81% 1.79%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.398M -$1.907B -$1.996M
YoY Change 26.2% 95400.18% 41.63%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $2.496M -$5.780M $1.700M
YoY Change -72.05% -440.0% -43.52%
Cash From Investing Activities $2.496M -$5.784B $1.698M
YoY Change -72.05% -340809.76% -43.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 866.1K $115.8M $175.0K
YoY Change 1632.28% 66071.43%
NET CHANGE
Cash From Operating Activities -2.398M -$1.907B -$1.996M
Cash From Investing Activities 2.496M -$5.784B $1.698M
Cash From Financing Activities 866.1K $115.8M $175.0K
Net Change In Cash 964.4K -$7.581B -$126.7K
YoY Change -86.38% 5983095.88% -107.97%
FREE CASH FLOW
Cash From Operating Activities -$2.398M -$1.907B -$1.996M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27554157
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39807659
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39747659
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27554157
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27494157
CY2021Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502
CY2021Q1 dyai Number Of Research Organizations
NumberOfResearchOrganizations
3 pure
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2020 dyai Deferred Tax Assets Valuation Allowance Coverage Percent
DeferredTaxAssetsValuationAllowanceCoveragePercent
1 pure
CY2017Q2 dyai Collaborative Arrangement Duration Of Agreement
CollaborativeArrangementDurationOfAgreement
P2Y
CY2017Q2 dyai Collaborative Arrangement Payment For Research And Development Agreement
CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
1100000 EUR
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
18900000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13055558 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20637045 USD
CY2021Q1 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
14177441 USD
CY2020Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
8457452 USD
CY2021Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
157201 USD
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
112247 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
384963 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
294199 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
216189 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
280555 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
27991352 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
29781498 USD
CY2021Q1 dyai Prepaid Research And Development In Process Current
PrepaidResearchAndDevelopmentInProcessCurrent
284709 USD
CY2020Q4 dyai Prepaid Research And Development In Process Current
PrepaidResearchAndDevelopmentInProcessCurrent
284709 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6151 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6225 USD
CY2021Q1 us-gaap Assets
Assets
28282212 USD
CY2020Q4 us-gaap Assets
Assets
30072432 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1473813 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1013099 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
277668 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
489756 USD
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
842248 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
123016 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2593729 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1625871 USD
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
39808 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
39748 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
98549890 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
98013079 USD
CY2021Q1 us-gaap Treasury Stock Value
TreasuryStockValue
18929915 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
18929915 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53971300 USD
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
25670 USD
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
168383 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3294949 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2214139 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
25688483 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3294949 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2214139 USD
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27533268
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27452490
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28446561 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
421071 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
115800 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3294949 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50676351 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
25688483 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28446561 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28282212 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30072432 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
460520 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
315372 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
390762 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
278182 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1808098 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
755453 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1554007 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1653392 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-28272 USD
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-10867 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
3781139 USD
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
2697894 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3320619 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2382522 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
421071 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
426939 USD
CY2021Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
63951 USD
CY2020Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
107256 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-28272 USD
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-10867 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
44954 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-102565 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
131800 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-35258 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-64297 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10529 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
480455 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-292361 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-212088 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-326000 USD
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
719232 USD
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
163799 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1906513 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1996345 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5783940 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1697615 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
115800 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
175000 USD
CY2021Q1 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
11283940 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-6834 USD
CY2020Q1 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
11652385 USD
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
5500000 USD
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
13350000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
115800 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
175000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2983 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7581487 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-126713 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20637045 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4823544 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13055558 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4696831 USD
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p>
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, the Company’s revenue was generated from <span style="-sec-ix-hidden:c73543764">eight</span> and <span style="-sec-ix-hidden:c73543765">five</span> customers, respectively. As of <em style="font: inherit;"> March 31, 2021</em> and <em style="font: inherit;"> December 31, 2020</em>, the Company’s accounts receivable was from <span style="-sec-ix-hidden:c73543766">seven</span> and <span style="-sec-ix-hidden:c73543767">nine</span> customers, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company’s customers could adversely affect its operations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, the Company had six customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 76.7% or $353,000 of the revenue. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2020</em>, the Company had three customers outside of the United States that accounted for approximately 58.0% or $183,000 of the revenue. As of the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, the Company had four customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 46.0% or $174,000 of accounts receivable. As of <em style="font: inherit;"> December 31, 2020</em>, the Company had seven customers outside of the United States that accounted for approximately 41.6% or $123,000 of accounts receivable.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company uses several contract research organizations (“CROs”) to conduct its research projects. As of and for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, <span style="-sec-ix-hidden:c73543786">three</span> CROs accounted for approximately $2,017,000 or 98.1% of total research services we purchased and $1,324,000 or 89.8% of the accounts payable. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2020, </em><span style="-sec-ix-hidden:c73543792">one</span> CRO accounted for approximately $855,000, or 100% of total research services we purchased. As of <em style="font: inherit;"> December 31, 2020</em>, <span style="-sec-ix-hidden:c73543795">one</span> CRO accounted for approximately $690,000 or 68.1% of the accounts payable. The loss of this CRO or a combination of the Company’s CROs could adversely affect its operations.</p>
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
384963 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
294199 USD
CY2021Q1 us-gaap Prepaid Insurance
PrepaidInsurance
94841 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
204988 USD
CY2021Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
120534 USD
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
72403 USD
CY2021Q1 us-gaap Prepaid Taxes
PrepaidTaxes
814 USD
CY2020Q4 us-gaap Prepaid Taxes
PrepaidTaxes
3164 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
216189 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
280555 USD
CY2021Q1 dyai Research And Development In Process Current
ResearchAndDevelopmentInProcessCurrent
1337755 USD
CY2020Q4 dyai Research And Development In Process Current
ResearchAndDevelopmentInProcessCurrent
904572 USD
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
93071 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
24496 USD
CY2021Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
42987 USD
CY2020Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
84031 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1473813 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1013099 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
447881 USD
CY2021Q1 dyai Accrued Research And Development In Process Current
AccruedResearchAndDevelopmentInProcessCurrent
42006 USD
CY2020Q4 dyai Accrued Research And Development In Process Current
AccruedResearchAndDevelopmentInProcessCurrent
28508 USD
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
60452 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13367 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
277668 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
489756 USD
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
175210 USD
CY2021Q1 dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
1659194 USD
CY2020Q1 dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
613790 USD
CY2021Q1 dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
148162 USD
CY2020Q1 dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
123638 USD
CY2021Q1 dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
742 USD
CY2020Q1 dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
18025 USD
CY2021Q1 dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
1808098 USD
CY2020Q1 dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
755453 USD
CY2021Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
10200000 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
9400000 USD
CY2021Q1 dyai Deferred Tax Assets Valuation Allowance Coverage Percent
DeferredTaxAssetsValuationAllowanceCoveragePercent
1 pure
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
6463 USD
CY2020Q4 us-gaap Investments And Cash
InvestmentsAndCash
29094496 USD
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5324215
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4663390
CY2021Q1 us-gaap Cash
Cash
1217419 USD
CY2021Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
11838139 USD
CY2021Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
13055558 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13055558 USD
CY2021Q1 dyai Cash Cash Equivalents And Investments Fair Value
CashCashEquivalentsAndInvestmentsFairValue
27216810 USD
CY2021Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
1658 USD
CY2021Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
17847 USD
CY2021Q1 us-gaap Investments And Cash
InvestmentsAndCash
27232999 USD
CY2020Q4 us-gaap Cash
Cash
149015 USD
CY2020Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
20488030 USD
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
20637045 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20637045 USD
CY2020Q4 dyai Cash Cash Equivalents And Investments Fair Value
CashCashEquivalentsAndInvestmentsFairValue
29110506 USD
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
22473 USD
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M2D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
12927908 USD
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.93
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
60000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0013 pure
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0055 pure
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5452 pure
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5607 pure
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4638390
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.44
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M20D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13701610 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
745825
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.25
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
60000
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.93
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5324215
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.84
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14209431 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4016141
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.28
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
421071 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
426939 USD
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.93
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.78
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28446561 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
421071 USD
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
115800 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3294949 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
25688483 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
35864471 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
426939 USD
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
175000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2214139 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
34252271 USD
CY2021Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502
CY2021Q1 us-gaap Treasury Stock Value
TreasuryStockValue
18900000 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001

Files In Submission

Name View Source Status
0001437749-21-012046-index-headers.html Edgar Link pending
0001437749-21-012046-index.html Edgar Link pending
0001437749-21-012046.txt Edgar Link pending
0001437749-21-012046-xbrl.zip Edgar Link pending
dyai-20200930_g1copy.jpg Edgar Link pending
dyai-20210331.xsd Edgar Link pending
dyai-20210331_cal.xml Edgar Link unprocessable
dyai-20210331_def.xml Edgar Link unprocessable
dyai-20210331_lab.xml Edgar Link unprocessable
dyai-20210331_pre.xml Edgar Link unprocessable
dyai20210331_10q.htm Edgar Link pending
dyai20210331_10q_htm.xml Edgar Link completed
ex_237822.htm Edgar Link pending
ex_237823.htm Edgar Link pending
ex_237824.htm Edgar Link pending
ex_237825.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending